Paper

0

Document

Submit new version

Download

Flag content

0

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia

Internal Medicine

Show More

Authors

Tingting Yang,Yetian Dong

Mingming Zhang,Jingjing Feng,Shan Fu,Pingnan Xiao,Ruimin Hong,Huijun Xu,Jiazhen Cui,Simao Huang,Guoqing Wei,Delin Kong,Jia Geng,Alex Chang,He Huang,Yongxian Hu

+14 authors

Journal

Experimental Hematology and Oncology

Published

Jan 3, 2025

DOI

10.1186/s40164-024-00593-5

Show more

Save

Tip

Document

Submit new version

Download

Flag content

0

Tip

Save

Document

Submit new version

Download

Flag content

Abstract

Sequential CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy offers a promising approach to antigen-loss relapse in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL); however, research in adults remains limited.

Paper PDF

Empty State

This PDF hasn't been uploaded yet.

Do not upload any copyrighted content to the site, only open-access content.

or